» Articles » PMID: 21693741

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

Overview
Journal JAMA
Specialty General Medicine
Date 2011 Jun 23
PMID 21693741
Citations 481
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Diabetes is the leading cause of kidney disease in the developed world. Over time, the prevalence of diabetic kidney disease (DKD) may increase due to the expanding size of the diabetes population or decrease due to the implementation of diabetes therapies.

Objective: To define temporal changes in DKD prevalence in the United States.

Design, Setting, And Participants: Cross-sectional analyses of the Third National Health and Nutrition Examination Survey (NHANES III) from 1988-1994 (N = 15,073), NHANES 1999-2004 (N = 13,045), and NHANES 2005-2008 (N = 9588). Participants with diabetes were defined by levels of hemoglobin A(1c) of 6.5% or greater, use of glucose-lowering medications, or both (n = 1431 in NHANES III; n = 1443 in NHANES 1999-2004; n = 1280 in NHANES 2005-2008).

Main Outcome Measures: Diabetic kidney disease was defined as diabetes with albuminuria (ratio of urine albumin to creatinine ≥30 mg/g), impaired glomerular filtration rate (<60 mL/min/1.73 m(2) estimated using the Chronic Kidney Disease Epidemiology Collaboration formula), or both. Prevalence of albuminuria was adjusted to estimate persistent albuminuria.

Results: The prevalence of DKD in the US population was 2.2% (95% confidence interval [CI], 1.8%-2.6%) in NHANES III, 2.8% (95% CI, 2.4%-3.1%) in NHANES 1999-2004, and 3.3% (95% CI, 2.8%-3.7%) in NHANES 2005-2008 (P <.001 for trend). The prevalence of DKD increased in direct proportion to the prevalence of diabetes, without a change in the prevalence of DKD among those with diabetes. Among persons with diabetes, use of glucose-lowering medications increased from 56.2% (95% CI, 52.1%-60.4%) in NHANES III to 74.2% (95% CI, 70.4%-78.0%) in NHANES 2005-2008 (P <.001); use of renin-angiotensin-aldosterone system inhibitors increased from 11.2% (95% CI, 9.0%-13.4%) to 40.6% (95% CI, 37.2%-43.9%), respectively (P <.001); the prevalence of impaired glomerular filtration rate increased from 14.9% (95% CI, 12.1%-17.8%) to 17.7% (95% CI, 15.2%-20.2%), respectively (P = .03); and the prevalence of albuminuria decreased from 27.3% (95% CI, 22.0%-32.7%) to 23.7% (95% CI, 19.3%-28.0%), respectively, but this was not statistically significant (P = .07).

Conclusions: Prevalence of DKD in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among persons with diabetes, prevalence of DKD was stable despite increased use of glucose-lowering medications and renin-angiotensin-aldosterone system inhibitors.

Citing Articles

Association Between Serum α-Klotho Levels and Diabetic Kidney Disease Prevalence in Middle-Aged and Elderly US Patients with Diabetes: A Cross-Sectional Study Using NHANES 2007-2016 Data.

Ding S, Sun J, Wang L, Wu L, Liu W Diabetes Ther. 2025; 16(3):499-511.

PMID: 39928222 PMC: 11868003. DOI: 10.1007/s13300-024-01683-7.


Untargeted metabolomic and proteomic analysis implicates SIRT2 as a novel therapeutic target for diabetic nephropathy.

Zhang R, Chang R, Wang H, Chen J, Lu C, Fan K Sci Rep. 2025; 15(1):4236.

PMID: 39905044 PMC: 11794435. DOI: 10.1038/s41598-024-80492-1.


Causal relationship between 412 gut microbiota, 1,400 blood metabolites, and diabetic nephropathy: a randomized Mendelian study.

Cao B, Zhang C, Wang Z, Wang Y Front Endocrinol (Lausanne). 2025; 15:1450428.

PMID: 39897958 PMC: 11782027. DOI: 10.3389/fendo.2024.1450428.


The relationship between cardiometabolic Index and diabetic kidney disease in people with diabetes.

Kong J, Tao W, Sun Y, Xu Y, Li H, Li J Front Endocrinol (Lausanne). 2025; 15():1376813.

PMID: 39850479 PMC: 11754048. DOI: 10.3389/fendo.2024.1376813.


Investigating the role of the metabolic score for visceral Fat in assessing the prevalence of chronic kidney disease from the NHANES 1999-2018.

Zhou X, Xiang J, Zhang S, Yang J, Tang Y, Wang Y Sci Rep. 2025; 15(1):2397.

PMID: 39827188 PMC: 11742988. DOI: 10.1038/s41598-025-86723-3.


References
1.
Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

2.
Kramer H, Nguyen Q, Curhan G, Hsu C . Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003; 289(24):3273-7. DOI: 10.1001/jama.289.24.3273. View

3.
. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

4.
. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003; 290(16):2159-67. PMC: 2622725. DOI: 10.1001/jama.290.16.2159. View

5.
Nathan D, Zinman B, Cleary P, Backlund J, Genuth S, Miller R . Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience.... Arch Intern Med. 2009; 169(14):1307-16. PMC: 2866072. DOI: 10.1001/archinternmed.2009.193. View